John Mendelson | OMICS International
ISSN: 2155-6105

Journal of Addiction Research & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

John Mendelson

John Mendelson Internist
Internal Medicine
California Pacific Medical Center


Dr. Mendelson performed many of the pharmacokinetic and abuse liability studies used to support FDA approval of Suboxone®—a new primary pharmacotherapy for opiate addiction. In collaboration with engineers, Dr. Mendelson and CPMCRI scientist Dr. Gantt Galloway are developing new technologies for detecting and treating opiate overdose, and improving adherence to prescription medications using Smart phones to track and verify medication administration. The Mendelson lab is developing more efficient clinical trials methodologies, such as portable devices that automate data collection outside the research clinic.

Research Interest

Methamphetamine, MDMA, cocaine, methamphetamine enantiomers, marijuana, and opioids), and evaluates pharmacotherapies for addictive disorders.


Global Speakers in the subject

Global Experts in the subject